About


Board of Directors

Steven Muskal, Ph.D.

Chief Executive Officer

Dr. Steven Muskal, founder of Sertanty, Inc. and Chief Executive Officer of Eidogen-Sertanty, has over 27 years of industry experience in technology development and marketing in the biopharmaceutical community, and more recently established the EidoPro nutraceutical brand. Before establishing Sertanty, Dr. Muskal served as Vice President of Informatics for Libraria, Inc., helping to secure financing while responsible for technology development and operational activity. Before joining Libraria, he served as Unit Director at the Affymax Research Institute and as a member of the Glaxo Wellcome Scientific Computing Board. At Affymax, Dr. Muskal directed departments focusing on advanced technologies in parallel synthesis, lead optimization (ADME), and research computing. Previously, he held positions as Product Manager, Senior Scientist, and Applications Scientist at MDL Information Systems, while designing, developing, and marketing chemical informatics software.

Dr. Muskal received his Doctorate in Biophysical Chemistry from the University of California, Berkeley and his B.Sc. in Engineering Chemistry and Computer Science from the Colorado School of Mines. He is a triathlete, plays amateur baseball, and is a drummer.

Shehan Dissanayake, Ph.D.

Director

Dr. Shehan Dissanayake is the CEO of Tavistock Life Sciences. He oversees all of TLS's operations and portfolio companies, including its investments in Eidogen-Sertanty, CovX, and Kalypsys. Prior to joining TLS, Shehan served as partner in charge of Strategy and Business Planning for Andersen's Global Tax, Human Resource, and Legal operating unit. Shehan received his B.A. in Biology and Chemistry at Skidmore College and a Ph.D. in Cell Physiology from The University of Chicago.

Chris Fuglesang, Ph.D.

Director

Dr. Fuglesang joined Tavistock Life Sciences in 2005. He has responsibilities for portfolio intellectual property, the management of existing portfolio companies, and the identification of prospective public and private investments. Prior to joining Tavistock, Dr. Fuglesang was Vice President at Eidogen, a structural proteomics software company, and a practicing attorney at Perkins Coie LLC in their biotechnology practice group. Dr. Fuglesang received a B.S. in both Chemistry and Physics from the University of California at Los Angeles, a Ph.D. in Theoretical Chemical Physics from the University of California at Los Angeles, and a J.D. from Boston University.

Roy Thiele-Sardiña

Director

Roy Thiele-Sardiña has over 20 years of computer technology experience. He was co-founder of Tasmania Network Systems, a cache proxy company that was acquired by Cisco Systems and a member of the founding management team for Brocade Communications Systems. Prior to Brocade, Mr. Thiele-Sardiña was responsible for Sun Microsystems's Corporate Development Organization in the office of the Chairman. Mr. Thiele-Sardiña holds Bachelor of Science degrees in Electrical Engineering and Computer Science from the University of Wisconsin-Madison, and an M.B.A. from New York University, Stern School of Business.

Guillermo Surraco

Director

Guillermo Surraco joined Technofyn Associates LLC as an Associate in 2000. Technofyn Associates LLC is an investment and venture capital firm whose principal owner is Dr. Alejandro Zaffaroni. Previously, Guillermo worked in the areas of marketing and sales for HSQ Technology and Landis & Gyr Systems Inc. He received a BS in Mechanical Engineering from Santa Clara University.

Malcolm Cloyd

Director

Malcolm Cloyd is a founder and managing member of the Athenaeum Fund. He has served as President, Vice President and General Manager of manufacturing and service businesses with domestic and international markets for over 27 years. He has directed business units that were the largest cash contributors for two major corporations and has conducted turnarounds of under-performing businesses for both large corporations and privately held companies. Mr. Cloyd has degrees in management, science and literature.